LEXEO Therapeutics LLC
Reshaping heart health through pioneering genetic medicine
New York, United States · Founded 2018 · $2.9M raised
- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2018
- Business Model
- B2B
- Website
- lexeotx.com
- Total Funding
- $2.9M
About
LEXEO Therapeutics is a clinical-stage genetic medicines company dedicated to transforming cardiovascular and CNS disease treatment through AAV-mediated gene therapy. Its pipeline targets inherited cardiac conditions including Friedreich's ataxia cardiomyopathy, arrhythmogenic cardiomyopathy, and APOE4-associated Alzheimer's disease. The company is publicly traded on NASDAQ (LXEO) and is headquartered in New York City.
Summary
LEXEO Therapeutics LLC is a Biotech company based in New York, United States, founded in 2018. It has raised $2.9M in total.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...